Counsyl
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $2.2m | Early VC | |
N/A | $11.1m | Early VC | |
N/A | $7.5m | Series A | |
$54.0m | Growth Equity VC | ||
$7.5m | Series C | ||
$28.0m | Series D | ||
$80.0m | - | ||
$375m | Acquisition | ||
Total Funding | CAD260m |
Related Content
Recent News about Counsyl
EditMyriad Women's Health, formerly known as Counsyl, specializes in genetic testing services aimed at reproductive health. The company operates in the healthcare sector, focusing on providing genetic screening and counseling services to individuals planning a pregnancy or concerned about their reproductive health. Myriad Women's Health serves a diverse range of clients, including patients, healthcare providers, and telehealth platforms. The business model revolves around offering genetic tests that can be ordered online or through healthcare providers, followed by detailed counseling sessions to interpret the results. Revenue is generated through the sale of these genetic tests and associated counseling services. The company leverages telehealth to make genetic testing more accessible, especially in the post-COVID-19 world, where remote healthcare solutions are increasingly in demand.
Keywords: genetic testing, reproductive health, telehealth, personalized care, healthcare, genetic counseling, telemedicine, patient education, remote solutions, reproductive risk.